Title: Vical Announces News Release and Conference Call Schedule for
Second Quarter 2007 Financial Results Date: 7/31/2007 6:30:00 AM
SAN DIEGO, July 31 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today
announced that the company will report financial results for the quarter ended June 30,
2007, before the opening of trading on Tuesday, August 7, and conduct a conference call
and webcast to discuss the financial results and provide a company update at noon Eastern
Time on Tuesday, August 7. The call is open on a listen-only basis to any interested
parties. The company will provide details on independent and partnered development
programs in the conference call and webcast.
To listen to the conference call, dial (888) 224-3260, or (913) 905-1086 for
international participants, and reference confirmation code 3989047. A replay of the call
will be available for 48 hours beginning about two hours after the call. To listen to the
replay, dial (888) 203-1112, or (719) 457-0820 for international participants, and enter
replay passcode 3989047. The call also will be available live and archived through the
events page at http://www.vical.com.
Invited analysts and institutional investors may ask questions during the conference
call. Others may submit questions before the call by e-mail addressed to info@vical.com or
by fax to (858) 646-1150. Submitted questions will be screened for appropriateness and
general interest. Selected questions received with sufficient notice before the call will
be answered as time permits at the end of the call. For further information, contact
Vical's Investor Relations department by phone at (858) 646-1127 or by e-mail at
info@vical.com.
About Vical
Vical researches and develops biopharmaceutical products based on its patented DNA
delivery technologies for the prevention and treatment of serious or life-threatening
diseases. Potential applications of the company's DNA delivery technology include DNA
vaccines for infectious diseases or cancer, in which the expressed protein is an
immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system
stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic
growth factor. The company is developing certain infectious disease vaccines and cancer
therapeutics internally. In addition, the company collaborates with major pharmaceutical
companies and biotechnology companies that give it access to complementary technologies or
greater resources. These strategic partnerships provide the company with mutually
beneficial opportunities to expand its product pipeline and address significant unmet
medical needs. Additional information on Vical is available at http://www.vical.com.
This press release contains forward-looking statements subject to risks and
uncertainties that could cause actual results to differ materially from those projected.
Forward-looking statements include statements about the company's focus, collaborative
partners, product candidates, and developmental status. Risks and uncertainties include
whether any product candidates will be shown to be safe and efficacious in clinical
trials, the timing of clinical trials, whether Vical or its collaborative partners will
seek or gain approval to market any product candidates, the dependence of the company on
its collaborative partners, and additional risks set forth in the company's filings with
the Securities and Exchange Commission. These forward-looking statements represent the
company's judgment as of the date of this release. The company disclaims, however, any
intent or obligation to update these forward-looking statements.
Contacts: Investors: Media:
Alan R. Engbring Susan Neath
Vical Incorporated Porter Novelli Life Sciences
(858) 646-1127 (619) 849-6007
Website: http://www.vical.com
SOURCE Vical Incorporated
-0- 07/31/2007
/CONTACT: investors, Alan R. Engbring of Vical Incorporated,
+1-858-646-1127; or media, Susan Neath of Porter Novelli Life Sciences,
+1-619-849-6007, for Vical Incorporated/
/Web site: http://www.vical.com /
(VICL)
CO: Vical Incorporated
ST: California
IN: BIO HEA MTC
SU: CCA
KF-AS
-- LATU010 --
2315 07/31/2007 06:30 EDT http://www.prnewswire.com
|